Expression, purification, and characterization of mouse CYP2D22

Aiming Yu, Robert L. Haining

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Metabolism of the prototype human CYP2D6 substrates debrisoquine and bufuralol proceeds at a much slower rate in mice; therefore, the mouse has been proposed as an animal model for the human CYP2D6 genetic deficiency. To interpret the molecular mechanism of this deficiency, a cDNA belonging to the CYP2D gene subfamily (Cyp2d22) has been cloned and sequenced from a mouse mammary tumor-derived cell line. In the current study, Cyp2d22 enzyme was overexpressed and purified from insect cells using a baculovirus-mediated system. The activity of this purified enzyme was directly compared with purified human CYP2D6 toward codeine, dextromethorphan, and methadone as substrates. Purified Cyp2d22 was found to catalyze the O-demethylation of dextromethorphan with significantly higher Km values (250 μM) than that (4.2 μM) exhibited by purified human CYP2D6. The Km for dextromethorphan N-demethylation by Cyp2d22 was found to be 418 μM, much lower than that observed with human CYP2D6 and near the Km for dextromethorphan N-demethylation catalyzed by CYP3A4. CYP2D6 catalyzed codeine O-demethylation, whereas Cyp2d22 and CYP3A4 mediated codeine N-demethylation. Furthermore, methadone, a known CYP3A4 substrate and CYP2D6 inhibitor, was N-demethylated by Cyp2d22 with a Km of 517 μM and Vmax of 4.9 pmol/pmol/min. Quinidine and ketoconazole, potent inhibitors to CYP2D6 and CYP3A4, respectively, did not show strong inhibition toward Cyp2d22-mediated dextromethorphan O-or N-demethylation. These results suggest that mouse Cyp2d22 has its own substrate specificity beyond CYP2D6-like-deficient activity.

Original languageEnglish (US)
Pages (from-to)1167-1174
Number of pages8
JournalDrug Metabolism and Disposition
Volume34
Issue number7
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP2D6
Dextromethorphan
Purification
Cytochrome P-450 CYP3A
Codeine
Methadone
Substrates
Debrisoquin
Quinidine
Ketoconazole
Baculoviridae
Medical Genetics
Enzymes
Substrate Specificity
Tumor Cell Line
Insects
Metabolism
Animal Models
Complementary DNA
Tumors

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Expression, purification, and characterization of mouse CYP2D22. / Yu, Aiming; Haining, Robert L.

In: Drug Metabolism and Disposition, Vol. 34, No. 7, 2006, p. 1167-1174.

Research output: Contribution to journalArticle

@article{aff7b9a0c8f2452baeedd78d75001333,
title = "Expression, purification, and characterization of mouse CYP2D22",
abstract = "Metabolism of the prototype human CYP2D6 substrates debrisoquine and bufuralol proceeds at a much slower rate in mice; therefore, the mouse has been proposed as an animal model for the human CYP2D6 genetic deficiency. To interpret the molecular mechanism of this deficiency, a cDNA belonging to the CYP2D gene subfamily (Cyp2d22) has been cloned and sequenced from a mouse mammary tumor-derived cell line. In the current study, Cyp2d22 enzyme was overexpressed and purified from insect cells using a baculovirus-mediated system. The activity of this purified enzyme was directly compared with purified human CYP2D6 toward codeine, dextromethorphan, and methadone as substrates. Purified Cyp2d22 was found to catalyze the O-demethylation of dextromethorphan with significantly higher Km values (250 μM) than that (4.2 μM) exhibited by purified human CYP2D6. The Km for dextromethorphan N-demethylation by Cyp2d22 was found to be 418 μM, much lower than that observed with human CYP2D6 and near the Km for dextromethorphan N-demethylation catalyzed by CYP3A4. CYP2D6 catalyzed codeine O-demethylation, whereas Cyp2d22 and CYP3A4 mediated codeine N-demethylation. Furthermore, methadone, a known CYP3A4 substrate and CYP2D6 inhibitor, was N-demethylated by Cyp2d22 with a Km of 517 μM and Vmax of 4.9 pmol/pmol/min. Quinidine and ketoconazole, potent inhibitors to CYP2D6 and CYP3A4, respectively, did not show strong inhibition toward Cyp2d22-mediated dextromethorphan O-or N-demethylation. These results suggest that mouse Cyp2d22 has its own substrate specificity beyond CYP2D6-like-deficient activity.",
author = "Aiming Yu and Haining, {Robert L.}",
year = "2006",
doi = "10.1124/dmd.105.008870",
language = "English (US)",
volume = "34",
pages = "1167--1174",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "7",

}

TY - JOUR

T1 - Expression, purification, and characterization of mouse CYP2D22

AU - Yu, Aiming

AU - Haining, Robert L.

PY - 2006

Y1 - 2006

N2 - Metabolism of the prototype human CYP2D6 substrates debrisoquine and bufuralol proceeds at a much slower rate in mice; therefore, the mouse has been proposed as an animal model for the human CYP2D6 genetic deficiency. To interpret the molecular mechanism of this deficiency, a cDNA belonging to the CYP2D gene subfamily (Cyp2d22) has been cloned and sequenced from a mouse mammary tumor-derived cell line. In the current study, Cyp2d22 enzyme was overexpressed and purified from insect cells using a baculovirus-mediated system. The activity of this purified enzyme was directly compared with purified human CYP2D6 toward codeine, dextromethorphan, and methadone as substrates. Purified Cyp2d22 was found to catalyze the O-demethylation of dextromethorphan with significantly higher Km values (250 μM) than that (4.2 μM) exhibited by purified human CYP2D6. The Km for dextromethorphan N-demethylation by Cyp2d22 was found to be 418 μM, much lower than that observed with human CYP2D6 and near the Km for dextromethorphan N-demethylation catalyzed by CYP3A4. CYP2D6 catalyzed codeine O-demethylation, whereas Cyp2d22 and CYP3A4 mediated codeine N-demethylation. Furthermore, methadone, a known CYP3A4 substrate and CYP2D6 inhibitor, was N-demethylated by Cyp2d22 with a Km of 517 μM and Vmax of 4.9 pmol/pmol/min. Quinidine and ketoconazole, potent inhibitors to CYP2D6 and CYP3A4, respectively, did not show strong inhibition toward Cyp2d22-mediated dextromethorphan O-or N-demethylation. These results suggest that mouse Cyp2d22 has its own substrate specificity beyond CYP2D6-like-deficient activity.

AB - Metabolism of the prototype human CYP2D6 substrates debrisoquine and bufuralol proceeds at a much slower rate in mice; therefore, the mouse has been proposed as an animal model for the human CYP2D6 genetic deficiency. To interpret the molecular mechanism of this deficiency, a cDNA belonging to the CYP2D gene subfamily (Cyp2d22) has been cloned and sequenced from a mouse mammary tumor-derived cell line. In the current study, Cyp2d22 enzyme was overexpressed and purified from insect cells using a baculovirus-mediated system. The activity of this purified enzyme was directly compared with purified human CYP2D6 toward codeine, dextromethorphan, and methadone as substrates. Purified Cyp2d22 was found to catalyze the O-demethylation of dextromethorphan with significantly higher Km values (250 μM) than that (4.2 μM) exhibited by purified human CYP2D6. The Km for dextromethorphan N-demethylation by Cyp2d22 was found to be 418 μM, much lower than that observed with human CYP2D6 and near the Km for dextromethorphan N-demethylation catalyzed by CYP3A4. CYP2D6 catalyzed codeine O-demethylation, whereas Cyp2d22 and CYP3A4 mediated codeine N-demethylation. Furthermore, methadone, a known CYP3A4 substrate and CYP2D6 inhibitor, was N-demethylated by Cyp2d22 with a Km of 517 μM and Vmax of 4.9 pmol/pmol/min. Quinidine and ketoconazole, potent inhibitors to CYP2D6 and CYP3A4, respectively, did not show strong inhibition toward Cyp2d22-mediated dextromethorphan O-or N-demethylation. These results suggest that mouse Cyp2d22 has its own substrate specificity beyond CYP2D6-like-deficient activity.

UR - http://www.scopus.com/inward/record.url?scp=33745245269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745245269&partnerID=8YFLogxK

U2 - 10.1124/dmd.105.008870

DO - 10.1124/dmd.105.008870

M3 - Article

C2 - 16595712

AN - SCOPUS:33745245269

VL - 34

SP - 1167

EP - 1174

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 7

ER -